















Effect of iodide-deficiency on rat mammary gland

- When rats are kept iodide-deficient, atrophy and necrosis takes place in the mammary gland and areas of dysplasia and atypia are seen.
- Administration of estradiol to iodide-deficient rats stimulates cell division in the gland and leads to the formation of alveoli.
- Continued stimulation by estradiol produces changes in the newly-formed alveolar cells. Their nucleoli are altered and show a separation of components. Ribosomes and lipid droplets increase and the cells synthesize large vacuoles containing protein.
- The secretion of great quantities of this material into areas of the tissue where regressive changes have occurred undoubtedly contributes to the formation of cysts within the gland.
- The present findings indicate that iodide-deficiency alters the structure and function of mammary gland alveolar cells and makes them highly sensitive to stimulation by estradiol.
- Effect of iodide-deficiency on rat mammary gland. Virchows Arch B Cell Pathol Incl Mol Pathol. 1979 May 31;30(2):209-20. doi: 10.1007/BF02889103. PMID: 38565.











DESERVEDENCES Akadre A. Vessey MP, McPherson K. Thyroid disease and breast cancer: findings in a large case-control study. Br J Surg. 1982;69:434–435. [PubMed] [Google Scholar] Surght PP, Smith PP, McPerroot EW, Murray MJ, Geraghty G, O'Higgins NJ. A direct relationship between thyroid enlargement and breast cancer. J Clin Endocrinol Methol. 1996;81:937–941. [PubMed] [Google Scholar] Surgia David David BL, Palmer L, Taylor S, Gooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999;85:696–705. [PubMed] [Google Scholar] Akina David David BL, Palmer L, Taylor S, Gooksley CS. Incidence of breast carcinoma in women with thyroid and mammary glands. Biol Trace Elem Res. 1995;49:69-705. [PubMed] [Google Scholar] Sichin BA, Orothowski CE, Connolly CP, Chent WR. Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res. 1995;49:29-203. [PubMed] [Google Scholar] Surgia Scholar Scholar (1996):12:209–213. [PubMed] [Google Scholar] Garcia-Solis P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, Diaz-Munor M, Yazquez-Martinez O, Aceves C. Inhibition of N-methyl-N-mitrosourca-induced pressing transmorter of the trace I syng holecular iodine (12) but not by iodide (15) treatment Evidence that 12 prevents cancer promotion. Molcell Endocrinol. 2005;23:64:53-240. [PubMed] [Google Scholar] Bester JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J. 2004;10:328-336. [PubMed] [Google Scholar]



Iodine 3 mg/d took 3 months Larger breasts and larger prostates, like BPH, need more iodine.

- A randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted with 111 otherwise healthy euthyroid women with a history of breast pain.
- Patients had to document moderate or severe breast pain by recording a score > or =5 on a visual analog scale (VAS) of pain for > or =6 days per cycle
 and had to present with fibrosis involving at least 25% of both breast surfaces. Subjects could not be effectively treated with more conservative
 measures such as local heat or nonprescription analgesics.
- There was not a statistically significant difference in the dropout rate for patients on placebo (11.8%), 1.5 mg/day (31.3%), 3.0 mg/day (18.4%), or 6.0 mg/day (25%) of molecular iodine for 6 months.
- Physicians assessed breast pain, tenderness, and nodularity each cycle; patients assessed breast pain and tenderness with the Lewin breast pain scale at 3-month intervals and with a VAS at each cycle.
- A statistically significant improvement (p < 0.01) associated with dose was observed in the Lewin overall pain scale for all treated groups compared to
 placebo.
- Reductions in all three physician assessments were observed in patients after 5 months of therapy in the 3.0 mg/day (7/28; 25%) and 6.0 mg/day (15/27; 18.5%) treatment groups, but not the 1.5 mg/day or placebo group.
- Patients recorded statistically significant decreases in pain by month 3 in the 3.0 and 6.0 mg/day treatment groups, but not the 1.5 mg/day or placebo group; more than 50% of the 6.0 mg/day treatment group recorded a clinically significant reduction in overall pain.
 All doses were associated with an acceptable safety profile.
- No dose-related increase in any adverse event was observed.
- The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J. 2004 Jul-Aug;10(4):328-36. doi: 10.1111/j.1075-122X.2004.21341.x. PMID: 15239792.

Eskin 1976

• Dietary iodine and cancer risk. Lancet. 1976 Oct 9;2(7989):807-8. doi: 10.1016/s0140-6736(76)90646-2. PMID: 61482.

15

Is iodine a gatekeeper of the integrity of the mammary gland? Iodolactones

- Iodine is natural anti-proliferative element in breast tissue.
- This paper reviews evidence showing iodine as an antioxidant and antiproliferative agent contributing to the integrity of normal mammary gland. Seaweed is an important dietary component in Asian communities and a rich source of iodine in several chemical forms. The high consumption of this element (25 times more than in Occident) has been associated with the low incidence of benign and cancer breast disease in Japanese women.
- In animal and human studies, molecular iodine (I(2)) supplementation exerts a suppressive effect on the development and size of both benign and cancer neoplasias. This effect is accompanied by a significant reduction in cellular lipoperoxidation. Iodine, in addition to its incorporation into thyroid hormones, is bound into antiproliferative iodolipids in the thyroid called iodolactones, which may also play a role in the proliferative control of mammary gland.
- We propose that an I(2) supplement should be considered as an adjuvant in breast cancer therapy.
- Is iodine a gatekeeper of the integrity of the mammary gland? J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):189-96. doi: 10.1007/s10911-005-5401-5. PMID: 16025225.
- Instituto de Neurobiología, Universidad Nacional Autónoma de México, Juriquilla.







Case Report MD Anderson Cancer PREVENTION Center

- 36 yo nullparous
- Dx 32 lobular hyperplasia
- Recommended 5 yrs of tamoxifen
- 3rd year SERM raloxifene
- Started to bleed
- Endometrial stripe slightly enlarged
- Recommended hysterectomy stat
- Gave iodine, new products, vaginal first pass progesterone,
- Post vaginal US normal within 6 weeks and able to avoid hysterectomy

Newest Thinking

- If high risk of cancer, then treat like you have cancer prophylactically to avoid cancer
- When in reality often need iodine, progesterone and get receptors to be working more optimally.



Iodine + P
Concerning the suppressive effect of inorganic iodine on the growth of 7,12-dimethyl-benz(a)anthracene (DMBA)-induced breast tumor in female Sprague-Dawley (SD) rats, we previously reported that although iodine itself had a suppressive effect on the tumor growth, its effect was not as strong as that of MPA (medroxy-progesterone acetate).
Iodine and progesterone – suppressive on bc proliferation.
However, the combined medication of iodine at a low concentration + MPA showed a stronger effect than MPA alone.
The purpose of the present study is to elucidate this mechanism of action by determining the uptake of the administered iodine into breast tumor tissue. Breast tumors were induced with DMBA in female SD rats, and these animals were treated with MPA + inorganic iodine at various concentrations for 4 weeks to determine tumor growth and tumor iodine content. In the comparison of tissue iodine content in growth-suppressive tumors with that in nonsuppressive tumors, the former showed a much higher iodine content.

• This suggests that direct uptake of inorganic iodine by breast tumors led to the suppression of tumor growth

 Suppressive effect of iodine on DMBA-induced breast tumor growth in the rat. J Surg Oncol. 1996 Mar;61(3):209-13. doi: 10.1002/(SICI)1096-9098(199603)61:3<209::AID-JSO9>3.0.CO;2-F. PMID: 8637209.





















Description of the present study hypothesize that progesterone withdrawal may underlie the decrement in D2 expression, with a subsidiary of 14 into 13 leading to a significant progesterone withdrawal may underlie the decrement in D2 expression, with a subsidiary of 14 into 13 leading to a significant progesterone withdrawal may underlie the decrement in D2 expression, with a subsidiary of 14 into 13 leading to a significant progesterone withdrawal may underlie the decrement in D2 expression, with a subsidiary of 14 into 13 leading to a significant progesterone withdrawal may underlie the decrement in D2 expression, with a subsidiary of 14 into 13 leading to 2 symptomized grave.



Drog uppedpad by the present study was to evaluate progesterone effects of progesterone of the sodiumor hyroid cells, so the aim of the present study was to evaluate progesterone effects in the sodiumor hyroid cells, so the aim of the present study was to evaluate progesterone effects in the sodiumthyroid tells, so the aim of the present study was to evaluate progesterone effects in the sodiumor hyroid cells, so the aim of the present study was to evaluate progesterone effects in the sodiumthyroid tells, derived from human tissue. *NIS, TG, TPO*, and *K1*-67 genes, expression in normal tyroid tollcular cells, derived from human tissue. *NIS, TG, TPO*, and *K1*-67 mRNA expression of *NIS*, TG, study after TS1 20 µU/µ. TSH plus 10 nP progesterone, RNA expression of *NIS*, TG, fine, p < 0.0001; and TPO mRNA expression also increased, though not significantly (1.77 times, P = 0.037; and 1.95 times, p < 0.0001, and TPO mRNA expression also increased, though not significantly (1.77 times, P = 0.030; and 1.95 times, p < 0.0001, and the presentence has a direct effect on free T3 thyroid cells, upregulate fine in thyroid cell function and growth. The soen round end thyroid to the trane to the tot the sodie the sodie to the tot tot tot. In the forcerine 10 to 20 15 20 15 26 48 552. doi: 10.1155/2015/864 852. Epub 2015 May 21. PMID: 260 89 895; p.MCD: PMC445 4767.



Hypothyroid

- Look at D levels
- Free T3 levels
- And consider PR in both genders.

Hormone Cross-Talk – before BHRT in perimenopause, fix thyroid and adrenal and possibly start with progesterone therapy

- Accumulating evidence has shown that thyroid hormones (THs) are vital for female reproductive system homeostasis. THs regulate the reproductive functions through thyroid hormone receptors (THRs)-mediated genomic- and integrin-receptor-associated nongenomic mechanisms, depending on TH ligand status and DNA level, as well as transcription and extra-nuclear signaling transduction activities. These processes involve the binding of THs to intracellular THRs and steroid hormone receptors or membrane receptors and the recruitment of hormone-response elements.
- In addition, THs and other reproductive hormones can activate common signaling pathways due to their structural similarity and shared DNA consensus sequences among thyroid, peptide, and protein hormones and their receptors, thus constituting a complex and reciprocal interaction network.
- Moreover, THs not only indirectly affect the synthesis, secretion, and action of reproductive hormones, but are also regulated by these hormones at the same time. This crosstalk may be one of the pivotal factors regulating female reproductive behavior and hormone-related diseases, including tumors. Elucidating the interaction mechanism among the aforementioned hormones will contribute to apprehending the etiology of female reproductive diseases, shedding new light on the treatment of gynecological disorders.
- A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females. Int J Mol Sci. 2022 Feb 28;23(5):2708. doi: 10.3390/ijms23052708. PMID: 35269847; PMCID: PMC8911152.



















Can use this for any hormone

kidneys (great with cytozyme KD) Adrenals (great with cytozyme AD) Heart (great with cytozyme H) Hypothalamus (great with cytozyme HT) Great with glucose balance Eyes Etc.

45

T3 is the active hormone

- T3 binds to thyroid receptor much greater than T4
- Decrease T3 conversion is always accompanied by increased conversion to reverse T3

Dr. DL. Berkson©











Thyroid Symptoms: • Thinning outer 1/3rd eyebrows • Thinning hair • Cold hands and feet! • Low body temp • Dark circles/puffy eyes • Dry skin • Slow transit time, history of constipation • Scalloped tongue (mild, moderate, severe) • Achilles reflex time (photomotogram, thyroflex)







Dr. DL. Berkson©







Tirosint

 Most medications used to treat hypothyroidism are tablets. In addition to levothyroxine, they contain a variety of excipients (inert ingredients) such as wheat starch (gluten), lactose, sugars, dyes and talc. These can sometimes cause irritation or make it harder for your body to absorb your thyroid medicine. The unique formulation of Tirosint helps to avoid these problems.





61

